By GuruFocus, Contributor The $26 billion T Rowe Price Equity Income Fund has been managed by the firm’s Chief Investment Officer Brian Rogers since 1985. Since then the fund has gained 11% a year on average. Over the past 10 years the fund averaged 9% a year. Brian Rogers likes to invest in companies that are well-established and pay above-average dividends. As we can see from his recent purchase, he likes to buy companies that are traded at 52-week lows, too.
Tag Archives: AMGN
Analyst Moves: ACT, AMGN
By MarketNewsVideo Actavis (ACT) had its estimates and price target increased by Morgan Stanley (MS) as the generic Pulicort settlement should remove some uncertainty about the company. An overweight rating was issued with a price target of $101. …read more
Source: FULL ARTICLE at Forbes Markets
IBB, AMGN, CELG, ALXN: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology Index Fund (NASD: IBB) where we have detected an approximate $48.0 million dollar inflow — that’s a 1.9% increase week over week in outstanding units (from 15,900,000 to 16,200,000). Among the largest underlying components of IBB, in trading today Amgen Inc (NASD: AMGN) is up about 0.8%, Celgene Corp. (NASD: CELG) is up about 1.5%, and Alexion Pharmaceuticals Inc. (NASD: ALXN) is up by about 1.2%. For a complete list of holdings, visit the IBB Holdings page » …read more
Source: FULL ARTICLE at Forbes Markets
Daily Dividends Report: AMGN, CVS, CSC, HRB, DK
By MarketNewsVideo Amgen Incorporated (AMGN) maintained its quarterly dividend of 47 cents per share. The dividend will be paid on June 7, 2013, to all stockholders of record as of the close of business on May 16, 2013. …read more
Source: FULL ARTICLE at Forbes Markets
Analyst Moves: AMGN, ATI
By MarketNewsVideo Amgen (AMGN) was downgraded by Credit Suisse (CS) to neutral from outperform with a price target of $90, as the stock is pricing in lower agency costs.
Source: FULL ARTICLE at Forbes Markets
Notable ETF Outflow Detected – IBB, AMGN, GILD, ALXN
By ETFChannel.com Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Nasdaq Biotechnology Index Fund (NASD: IBB) where we have detected an approximate $66.0 million dollar outflow — that’s a 3.0% decrease week over week (from 15,200,000 to 14,750,000). Among the largest underlying components of IBB, in trading today Amgen Inc (NASD: AMGN) is off about 0.8%, Gilead Sciences, Inc. (NASD: GILD) is trading flat, and Alexion Pharmaceuticals Inc. (NASD: ALXN) is lower by about 1.8%. For a complete list of holdings, visit the IBB Holdings page »
Source: FULL ARTICLE at Forbes Markets